Investment

#Drug development #Finance #Investment

Boyds records growth following investment strategy  

Global drug development consultancy Boyds has reported strong financial growth following a two-year strategy to expand its business.  Boyds saw an increase of over 20% year-on-year in annual revenue in the wake of increased demand for drug development expertise across the UK, US, and Europe. … Read More

#News

#Funding #Investment

New biopharma deals report reveals spending trends 

Clarivate has released its annual Biopharma Deals Report, which highlights emerging market trends and features detailed analysis of the key deals of 2021 and potential implications for 2022, the full extent of which can be found on clarivate.com.  This year’s report finds US biotech companies raised the majority of capital… Read More

#News #Trends & Analysis

#Drug development #Drug innovation #Funding #Investment

CatSci secures £4.5 million funding deal for drug development 

CatSci, a partner for medicines development, has secured £4.5 million of investment to expedite the development and launch of what it calls its life-changing therapeutics.  The company develops economically and environmentally sustainable drug manufacturing processes that enable its global pharmaceutical customers to create affordable small molecule therapeutics… Read More

#News

#Collaboration #Funding #Investment

CellCentric secures investment to advance targeted cancer therapy 

CellCentric has received funding from BrightEdge to further progress the clinical development of its targeted treatment, inobrodib (formerly known as CCS1477) and are accompanied by additional investment from existing lead investor, Morningside Investments Limited.  What is inobrodib?  Inobrodib is a first-in-class small molecule inhibitor that impacts twin regulatory proteins p300… Read More

#News

#Drug discovery #Funding #Healthcare #Investment #Life sciences #Public health

Drug discovery investors: Who’s spending? 

While the research, results and trials often take centre-stage when it comes to drug discovery and development reporting, DDW’s Megan Thomas spotlights the funding and investments which make this possible.   1. US researcher awarded $3.6 million to study antibiotic resistance  Sanford Burnham Prebys professor Andrei Osterman, Ph.D., has been awarded a $3.6 million… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News

#Biopharmaceuticals #Biotechnology #Drug development #Investment #Pharmaceuticals #Therapeutics

New laboratory boosts high-potency drug development

US-based Continuus Pharmaceuticals has opened a new laboratory space and new technology to help the development of high-potency drugs. The new lab and technology are the latest developments in Continuus’ ongoing expansion, coming six months after receiving a US$69.3 million US government contract for the domestic production of medicines. “Our… Read More

#News

#Covid-19 #Investment #Life sciences #Public health #Social enterprise

Mologic becomes a ‘social enterprise’ following acquisition

A group of philanthropic funds and investors led by the Soros Economic Development Fund (SEDF), with support from the Bill & Melinda Gates Foundation, has launched Global Access Health (GAH), a social enterprise that aims to expand access to affordable medical technology. The group has financed the acquisition of Mologic,… Read More

#News